Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ovarian cancer
Biotech
Genmab ph. 2 data spur claim ADC ‘clearly superior’ to Elahere
Genmab reported progression-free survival of 9.5 months, leading TD Cowen analysts to hail the asset as “clearly superior” to AbbVie’s Elahere.
Nick Paul Taylor
Oct 5, 2026 4:14am
ASCO: Tubulis touts ovarian cancer data that attracted Gilead
May 30, 2026 9:36am
OSE turns up the heat on ovarian cancer with phase 2 win
May 22, 2026 7:14am
Ascendis axes IL-2 program in retreat from oncology expansion
May 7, 2026 10:10am
GSK CEO’s ‘scientific courage’ propels ADC toward ph. 3 tests
Apr 12, 2026 10:10am
Accent halts DHX9 inhibitor trial over adverse events
Feb 26, 2026 5:01am
